ReviewWorld journal of gastroenterology2023
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis.
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses.BMC cardiovascular disorders · 2025Pooled it
- Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review.International journal of molecular sciences · 2025Pooled it
- The cholesterol, high-density lipoprotein, and glucose index and its derivatives related to obesity and inflammation as novel metabolic markers for predicting new-onset cardiovascular-liver-metabolic multimorbidity: A prospective cohort study.Journal of diabetes investigation · 2026Article
- Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease.Veterinary sciences · 2026Review
- Interrelationship Between Sarcopenia, Frailty and Cardiovascular Disease-The Crucial Role of Obesity in Hypothesis Generation-A Narrative Review.Journal of personalized medicine · 2026Review
- Glycosylation modification: a trigger for obesity and its complications?Molecular medicine (Cambridge, Mass.) · 2026Review
- Uric Acid-to-HDL Cholesterol Ratio Is Associated with Prediabetes and an Adverse Metabolic Profile: Results from the Genetics of Atherosclerotic Disease (GEA) Study.Diagnostics (Basel, Switzerland) · 2026Article
- Associations of the insulinemic potential of diet and lifestyle with metabolic dysfunction-associated steatotic liver disease (MASLD) risk in adults with type 2 diabetes.Scientific reports · 2026Article
- Micro- and Nanoplastics as Emerging Drivers of Liver Injury: Exposure, Evidence, and Mechanisms.International journal of molecular sciences · 2026Review
- Natural Plant-Derived Compounds Targeting Oxidative Stress and Inflammation in NAFLD-Mechanisms and Repositioning Potential.Current issues in molecular biology · 2026Review
- The evaluation of an HIV-PrEP drug on the vascular health outcomes in a diet-induced prediabetes condition rat model.Scientific reports · 2026Article
- Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors.Nutrients · 2026Review
- Comparing the diagnostic performance of metabolic indices in metabolic dysfunction-associated fatty liver disease patients: a retrospective cross-sectional study.European journal of medical research · 2026Article
- Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study.American journal of preventive cardiology · 2026Article
- Long-term liver stiffness dynamics after sustained virological response in patients with HIV/HCV co-infection and advanced fibrosis.AIDS (London, England) · 2026Article
- The Multifaceted Role of Cytochrome P450 Isoenzymes in Alcoholic and Metabolic (Dysfunction) Fatty Liver Diseases.Current drug metabolism · 2026Review
- Body Mass Index Outperforms Triglyceride-Glucose Index in Predicting MAFLD in Type 2 Diabetes: A Cross-Sectional Mediation and Interaction Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Association of prediabetes phenotypes with metabolic dysfunction-associated fatty liver disease and liver fibrosis: a population-based study.Therapeutic advances in endocrinology and metabolism · 2026Article
- Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad.European journal of clinical investigation · 2026Review
- Artificially fermented dark loose tea ameliorates metabolic-associated fatty liver disease by activating the PI3K/AKT signalling pathway and regulating gut microbiota dysbiosis.Food chemistry: X · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between metabolic derangements and fatty liver development are undeniable, since more than 75% of patients with type 2 diabetes mellitus present with fatty liver. There is also significant epidemiological association between insulin resistance (IR) and metabolic (dysfunction)-associated fatty liver disease (MAFLD). For little more than 2 years, the nomenclature of fatty liver of non-alcoholic origin has been intended to change to MAFLD by multiple groups. While a myriad of reasons for which MAFLD is thought to be of metabolic origin could be exposed, the bottom line relies on the role of IR as an initiator and perpetuator of this disease. There is a reciprocal role in MAFLD development and IR as well as serum glucose concentrations, where increased circulating glucose and insulin result in increased
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.